Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRO-1562
- Development stage
- Phase 2
- Lead developer
- Korro Bio
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PRO-1562 is an orally administered, first-in-class small molecule platelet-derived growth factor receptor alpha (PDGFRα) inhibitor originally developed by Frequency Therapeutics and subsequently acquired and advanced by Progentos Therapeutics. It is designed to promote the differentiation of oligodendrocyte progenitor cells (OPCs) into mature, myelin-producing oligodendrocytes, thereby stimulating endogenous remyelination of demyelinated axons in the central nervous system. PRO-1562 is being evaluated in a Phase 1/2a clinical trial for the treatment of relapsing multiple sclerosis (RMS) and chronic optic neuropathy, aiming to restore neurological function and prevent axonal degeneration.
02
Targets
PDGFRA (Platelet-derived growth factor receptor alpha)
Beyond the preview
Go deeper on PRO-1562.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRO-1562.